Treatment of Neurocardiogenic Syncope

Initial Non-Pharmacological Management

The European Society of Cardiology recommends behavior modification as the first-line treatment for neurocardiogenic syncope, including increased fluid and salt intake, physical counterpressure maneuvers, and pharmacological therapy only when these measures fail 1, 2
Adequate hydration and salt intake must be maintained as a foundational treatment approach, as recommended by the European Heart Journal 3
Physical counterpressure maneuvers, such as leg crossing and squatting, are helpful in many patients with neurocardiogenic syncope, according to the European Heart Journal 2
Avoidance of triggering situations, such as prolonged standing, crowded hot places, or situations that previously triggered episodes, is recommended for patients with neurocardiogenic syncope 4

Midodrine (5-20 mg, three times daily) should be administered as adjunctive therapy if needed, particularly in patients with frequent presyncope or syncope, as recommended by the European Heart Journal 3
Fludrocortisone (0.1-0.3 mg once daily) should be administered as adjunctive therapy if needed, particularly when initial non-pharmacological measures fail, according to the European Heart Journal 3, 2
Beta-blockers have been used in uncontrolled studies, but their routine use is discouraged due to limited evidence, as stated by the European Heart Journal 2

Pacemaker therapy should be avoided whenever possible in cardioinhibitory syncope, with pharmacological therapy preferred as an alternative, as recommended by the European Heart Journal 2
Additional treatments, such as desmopressin, octreotide, erythropoietin, and pyridostigmine, may be considered in specific situations, according to the European Heart Journal 3

The initial approach to treating neurocardiogenic syncope should involve lifestyle modifications, including increased fluid and salt intake, and physical counterpressure maneuvers, as recommended by the European Heart Journal 2
If symptoms persist, fludrocortisone may be considered as an adjunctive therapy, according to the European Heart Journal 3
For refractory cases, specialized referral for combination therapy or investigational approaches may be necessary, as stated by the European Heart Journal 5

Despite adequate treatment, syncope may recur in approximately 20% of patients during long-term follow-up, according to the European Heart Journal 5
Patients with cardiac disease require additional evaluation for potential cardiac causes of syncope before assuming a neurocardiogenic mechanism, as recommended by the European Heart Journal 6

Repeat tilt testing to assess therapy response has no proven predictive value, as stated by the European Heart Journal 2
For patients with infrequent episodes, close follow-up without extensive evaluation may be appropriate, according to the European Heart Journal 6